100 Campus Drive
Florham Park, NJ 07932
United States
608 441 8120
https://www.cellectar.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 20
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. James V. Caruso | President, CEO & Director | 846.48k | N/A | 1959 |
Mr. Chad J. Kolean CPA | VP, CFO & Secretary | 453.22k | N/A | 1964 |
Mr. Jarrod Longcor | Chief Operating Officer | 625.32k | N/A | 1973 |
Mr. Darrell Shane Lea | Chief Commercial Officer | N/A | N/A | 1973 |
Dr. Andrei Shustov M.D. | Senior Vice President of Medical | N/A | N/A | 1971 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Cellectar Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.